研究人員>潘建雄 (Chien-Hsiung Pan)

感染症與疫苗研究所

連絡電話:(+886) 037-246166 ext. 37727

傳真電話:(+886) 037-583009

電子郵箱:cpan@nhri.org.tw

 

學歷

1996/09 – 2001/10 Ph.D., Graduate Institute of Life Sciences, National Defense Medical College, Taiwan
1993/09 – 1995/06 M.S., Graduate Institute of Immunology, National Taiwan Univ., Taiwan
1986/09 – 1990/06 B.S, Medical Technology, National Taiwan Univ., Taiwan

經歷

2016/03 – present Associate Investigator, National Institute of Infectious Diseases nd Vaccinology, National Health Research Institutes, Taiwan
2008/03 – 2016/03 Assistant Investigator, Vaccine Research and Development Center, National Health Research Institutes, Taiwan
2005/01 – 2007/12 Research Associate, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA
2002/01 – 2004/12 Postdoctoral Fellow, Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA
1995/09 – 1996/08 Research Assistant, Graduate Institutes of Clinical Medicine, National Taiwan University, Taipei, Taiwan
1992/07 – 1993/07 Research Assistant, Department of Medical Technology, Chang-Gung Medical College, Taiwan
1990/10 – 1992/05 Administrator, medical record department, 817 Army Hospital, Taiwan

Honors & Awards

2003 – 2005 Scholarship from the Gilbert F. Otto Young Investigator Fund, Johns Hopkins University, U.S.A.
2002 – 2003 Postdoctoral fellowship from Dept. Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, U.S.A
2001 – 2001 PhD Student Thesis Research Award, Institute of Life Sciences, National Defense Medical College, Taiwan
1999 – 1999 Travel Award from the Foundation for The Advancement of Outstanding Scholarship, Taiwan

Research Interests

My interests focus on the interaction between host immune system and infectious viruses, particular in the fields of viral pathogenesis and vaccine R&D. I used genetic vaccine and recombinant viral vector to study how the host immunity was induced and modulated against virus infection, particular in measles virus (MV), Japanese encephalitis virus (JEV) and hepatitis C virus. In additional, I also investigated the protective mechanism of JEV infection, and the pathogenesis of MV persistence. My ongoing project is to develop a therapeutic cancer vaccine based on the knowledge of recombinant viral vector. SPECIAL FIELD Development of recombinant measles viral vector and biocompatible microparticle vaccine delivery system.

  1. Experienced in the evaluation of vaccine immunogenicity in animal models (mouse and rhesus macaque).
  2. Specialized in the R&D of vaccine delivery system, including a measles viral vector and microparticle formulated subunit vaccine
  3. R&D in vaccine against flavivirus viruses, including Japanese encephalitis virus and dengue virus.
  4. The host immunity required for the defense of invasive candidiasis.

Research Activities & Accomplishment

  1. I have conducted two vaccine monkey trials, including dengue EDIII subunit vaccine and EV71 inactivated virus vaccine and contributed to the future application of these vaccine candidates in human.
  2. I have developed a recombinant measles viral vector for vaccine and oncolytic tumor therapy.
  3. I have developed a biodegradable cationic microparticle for protein and DNA vaccine delivery.
  4. I have successfully established a mouse model for Candida alibicans colonization in guts and invasion relevant to clinical progression.

PATENTS 1. Cationic biodegradable polyceramic microparticles for vaccine delivery. (NHRI ITTC: 105004, submitted) MEMBERSHIP Member          Association of Molecular and Cellular Biology, R. O. C. (1999) Member          American Society for Virology (2007) Member          American Association of Immunology (2007)

Research Grant Participation

  1. Development of a Candida mucosal/systemic infection mouse model to evaluate diagnostic biomarkers or therapeutic targets. MOST 104-2314-B-400-025- (1/3); 2015/8/1 to 2016/7/31
  2. Evaluation of the potency of the viral vector dengue vaccine: Using the interferon receptor gene knockout mouse as an animal model. MOST 103-2320-B-400-016-MY3; 2014/8/1 to 2017/7/31
  3. Development of a tetravalent dengue vaccine delivered by a measles viral vector.  NSC 99-2320-B-400-004-MY3; 2010/8/1 to 2013/7/31.

NHRI Repository

Comments are closed.